Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBU Caribou Biosciences	$2.05 +12.0%	$1.26	$0.66 ▼ $3.00	$190.66M	2.48	1.28 million shs	2.96 million shs
IPHA Innate Pharma	$1.92 +8.5%	$1.96	$1.29 ▼ $3.51	$176.98M	0.21	187,954 shs	17,431 shs
ITRM Iterum Therapeutics	$0.92 -6.5%	$0.98	$0.81 ▼ $3.02	$36.66M	2.79	1.09 million shs	1.81 million shs
NXTC NextCure	$4.99 -2.7%	$5.67	$2.69 ▼ $21.48	$13.35M	1.06	11,618 shs	29,253 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBU Caribou Biosciences	0.00%	+25.77%	+60.16%	+178.91%	-22.35%
IPHA Innate Pharma	0.00%	+10.14%	+1.05%	-2.54%	-12.73%
ITRM Iterum Therapeutics	0.00%	-18.88%	-8.34%	-15.13%	-28.95%
NXTC NextCure	0.00%	+5.27%	-8.12%	+15.13%	-76.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRBU Caribou Biosciences	2.0261 of 5 stars	3.5	3.0	0.0	0.0	1.7	0.6
IPHA Innate Pharma	1.8697 of 5 stars	3.8	3.0	0.0	0.0	1.7	0.0
ITRM Iterum Therapeutics	1.4038 of 5 stars	3.5	3.0	0.0	0.6	0.0	0.0
NXTC NextCure	4.2319 of 5 stars	3.4	3.0	4.3	1.5	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRBU Caribou Biosciences	3.00	Buy	$8.50	314.63% Upside
IPHA Innate Pharma	3.50	Strong Buy	$11.00	472.92% Upside
ITRM Iterum Therapeutics	3.00	Buy	$9.00	881.89% Upside
NXTC NextCure	2.75	Moderate Buy	$33.00	561.32% Upside

Current Analyst Ratings Breakdown

Latest ITRM, CRBU, NXTC, and IPHA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	NXTC NextCure	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$36.00 ➝ $15.00
7/8/2025	NXTC NextCure	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/1/2025	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00
5/8/2025	ITRM Iterum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$9.00
4/28/2025	CRBU Caribou Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $3.00
4/24/2025	IPHA Innate Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.50 ➝ $11.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRBU Caribou Biosciences	$9.99M	19.08	N/A	N/A	$2.79 per share	0.73
IPHA Innate Pharma	$12.62M	14.02	N/A	N/A	$0.11 per share	17.45
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	($0.15) per share	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	$28.06 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRBU Caribou Biosciences	-$149.10M	-$1.62	N/A	N/A	N/A	-1,490.84%	-55.70%	-45.35%	8/5/2025 (Estimated)
IPHA Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
ITRM Iterum Therapeutics	-$24.77M	-$0.99	N/A	∞	N/A	N/A	N/A	-71.37%	8/13/2025 (Estimated)
NXTC NextCure	-$55.65M	-$21.13	N/A	N/A	N/A	N/A	-70.16%	-58.10%	7/30/2025 (Estimated)

Latest ITRM, CRBU, NXTC, and IPHA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ITRM Iterum Therapeutics	-$0.13	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	NXTC NextCure	-$0.39	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	CRBU Caribou Biosciences	-$0.40	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	ITRM Iterum Therapeutics	-$0.14	-$0.14	N/A	-$0.14	N/A	N/A
5/8/2025	Q1 2025	CRBU Caribou Biosciences	-$0.43	-$0.43	N/A	-$0.43	$1.48 million	$2.35 million
5/1/2025	Q1 2025	NXTC NextCure	-$4.80	-$4.68	+$0.12	-$0.39	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRBU Caribou Biosciences	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRBU Caribou Biosciences	N/A	7.63	7.63
IPHA Innate Pharma	2.52	2.60	2.60
ITRM Iterum Therapeutics	N/A	3.72	3.58
NXTC NextCure	N/A	10.26	10.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRBU Caribou Biosciences	77.51%
IPHA Innate Pharma	0.16%
ITRM Iterum Therapeutics	9.21%
NXTC NextCure	42.65%

Insider Ownership

Company	Insider Ownership
CRBU Caribou Biosciences	8.28%
IPHA Innate Pharma	31.89%
ITRM Iterum Therapeutics	9.20%
NXTC NextCure	17.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRBU Caribou Biosciences	100	93.00 million	85.30 million	Optionable
IPHA Innate Pharma	220	92.18 million	62.78 million	Not Optionable
ITRM Iterum Therapeutics	10	40.00 million	36.32 million	Not Optionable
NXTC NextCure	90	2.68 million	2.20 million	Optionable

ITRM, CRBU, NXTC, and IPHA Headlines

Recent News About These Companies

NextCure (NASDAQ:NXTC) Given New $15.00 Price Target at Piper Sandler

July 15, 2025 | marketbeat.com

NextCure, Inc. (NXTC) - Yahoo Finance

July 11, 2025 | nz.finance.yahoo.com

NextCure shareholders approve board elections and reverse stock split proposal

June 25, 2025 | uk.investing.com

NextCure shareholders approve board elections and reverse stock split proposal - Investing.com

June 25, 2025 | investing.com

Nextcure stock drops near 30% on $745M ADC deal with Simcere

June 18, 2025 | bioworld.comB

NextCure Joins China-ADC Gold Rush with $745M Simcere Deal

June 17, 2025 | biospace.comB

NextCure tanks as it teams up with Simcere on novel ADC

June 17, 2025 | thepharmaletter.comT

NextCure advances ADC pivot with $745M deal for Simcere’s phase 1 drug

June 16, 2025 | fiercebiotech.comF

NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline

June 16, 2025 | msn.com

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug

June 16, 2025 | reuters.com

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

June 16, 2025 | globenewswire.com

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ...

May 30, 2025 | morningstar.comM

NextCure, Inc. and LigaChem Biosciences Announce Phase 1 Study of LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, to be Presented at ASCO 2025

May 30, 2025 | nasdaq.com

NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024

May 29, 2025 | insidermonkey.com

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

May 29, 2025 | globenewswire.com

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

May 2, 2025 | taiwannews.com.twT

NextCure Provides Business Update andÂ Reports First Quarter 2025 Financial Results

May 1, 2025 | globenewswire.com

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

April 4, 2025 | globenewswire.com

H.C. Wainwright says competitor data builds optimism for NextCure’s LNCB74

March 17, 2025 | markets.businessinsider.com

Piper Sandler Sticks to Its Buy Rating for NextCure (NXTC)

March 8, 2025 | markets.businessinsider.com

NextCure Reports 2024 Financials and Strategic Progress

March 7, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITRM, CRBU, NXTC, and IPHA Company Descriptions

Caribou Biosciences NASDAQ:CRBU

$2.05 +0.22 (+12.02%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.05 0.00 (0.00%)

As of 07/18/2025 07:47 PM Eastern

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Innate Pharma NASDAQ:IPHA

$1.94 +0.16 (+9.30%)

As of 07/18/2025 03:57 PM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Iterum Therapeutics NASDAQ:ITRM

$0.92 -0.06 (-6.47%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.92 +0.00 (+0.37%)

As of 07/18/2025 07:54 PM Eastern

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

NextCure NASDAQ:NXTC

$4.99 -0.14 (-2.73%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.05 +0.06 (+1.20%)

As of 07/18/2025 07:16 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time